Company

ARCA biopharma, Inc.

Headquarters: Westminster, CO, United States

Employees: 17

CEO: Dr. Michael R. Bristow M.D., Ph.D.

NASDAQ: ABIO -16.75%

Market Cap

$23.5 Million

USD as of Jan. 1, 2024

Market Cap History

ARCA biopharma, Inc. market capitalization over time

Evolution of ARCA biopharma, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of ARCA biopharma, Inc.

Detailed Description

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

ARCA biopharma, Inc. has the following listings and related stock indices.


Stock: NASDAQ: ABIO wb_incandescent

Stock: FSX: HQ10 wb_incandescent

Details

Headquarters:

10170 Church Ranch Way

Suite 100

Westminster, CO 80021

United States

Phone: 720 940 2100